Switch theme
Sign up to access all valuation multiples
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
2014
750
LTM Revenue $28.2M
LTM EBITDA -$1.0B
$2.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Roivant Sciences has a last 12-month revenue (LTM) of $28.2M and a last 12-month EBITDA of -$1.0B.
In the most recent fiscal year, Roivant Sciences achieved revenue of $29.1M and an EBITDA of -$1.1B.
Roivant Sciences expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Roivant Sciences valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $28.2M | XXX | $29.1M | XXX | XXX | XXX |
| Gross Profit | $25.3M | XXX | $28.1M | XXX | XXX | XXX |
| Gross Margin | 90% | XXX | 97% | XXX | XXX | XXX |
| EBITDA | -$1.0B | XXX | -$1.1B | XXX | XXX | XXX |
| EBITDA Margin | -3589% | XXX | -3785% | XXX | XXX | XXX |
| EBIT | -$911M | XXX | -$1.1B | XXX | XXX | XXX |
| EBIT Margin | -3230% | XXX | -3833% | XXX | XXX | XXX |
| Net Profit | -$289M | XXX | -$172M | XXX | XXX | XXX |
| Net Margin | -1023% | XXX | -592% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Roivant Sciences's stock price is $11.
Roivant Sciences has current market cap of $7.5B, and EV of $2.7B.
See Roivant Sciences trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $2.7B | $7.5B | XXX | XXX | XXX | XXX | $-0.39 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Roivant Sciences has market cap of $7.5B and EV of $2.7B.
Roivant Sciences's trades at 50.5x EV/Revenue multiple, and 10.6x EV/EBITDA.
Equity research analysts estimate Roivant Sciences's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Roivant Sciences has a P/E ratio of -25.8x.
See valuation multiples for Roivant Sciences and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $7.5B | XXX | $7.5B | XXX | XXX | XXX |
| EV (current) | $2.7B | XXX | $2.7B | XXX | XXX | XXX |
| EV/Revenue | 94.8x | XXX | 50.5x | XXX | XXX | XXX |
| EV/EBITDA | -2.6x | XXX | 10.6x | XXX | XXX | XXX |
| EV/EBIT | -2.9x | XXX | -2.4x | XXX | XXX | XXX |
| EV/Gross Profit | 105.6x | XXX | n/a | XXX | XXX | XXX |
| P/E | -25.8x | XXX | 7.8x | XXX | XXX | XXX |
| EV/FCF | -8.0x | XXX | -3.2x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialRoivant Sciences's last 12 month revenue growth is 42%
Roivant Sciences's revenue per employee in the last FY averaged $39K, while opex per employee averaged $1.5M for the same period.
Roivant Sciences's rule of 40 is 519% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Roivant Sciences's rule of X is -3484% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Roivant Sciences and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 42% | XXX | 35% | XXX | XXX | XXX |
| EBITDA Margin | -3589% | XXX | 477% | XXX | XXX | XXX |
| EBITDA Growth | 26% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | 519% | XXX | 519% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -3484% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $39K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1895% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 3930% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Roivant Sciences acquired XXX companies to date.
Last acquisition by Roivant Sciences was XXXXXXXX, XXXXX XXXXX XXXXXX . Roivant Sciences acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Roivant Sciences founded? | Roivant Sciences was founded in 2014. |
| Where is Roivant Sciences headquartered? | Roivant Sciences is headquartered in United States of America. |
| How many employees does Roivant Sciences have? | As of today, Roivant Sciences has 750 employees. |
| Who is the CEO of Roivant Sciences? | Roivant Sciences's CEO is Mr. Matthew Gline. |
| Is Roivant Sciences publicy listed? | Yes, Roivant Sciences is a public company listed on NAS. |
| What is the stock symbol of Roivant Sciences? | Roivant Sciences trades under ROIV ticker. |
| When did Roivant Sciences go public? | Roivant Sciences went public in 2021. |
| Who are competitors of Roivant Sciences? | Similar companies to Roivant Sciences include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Roivant Sciences? | Roivant Sciences's current market cap is $7.5B |
| What is the current revenue of Roivant Sciences? | Roivant Sciences's last 12 months revenue is $28.2M. |
| What is the current revenue growth of Roivant Sciences? | Roivant Sciences revenue growth (NTM/LTM) is 42%. |
| What is the current EV/Revenue multiple of Roivant Sciences? | Current revenue multiple of Roivant Sciences is 94.8x. |
| Is Roivant Sciences profitable? | Yes, Roivant Sciences is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Roivant Sciences? | Roivant Sciences's last 12 months EBITDA is -$1.0B. |
| What is Roivant Sciences's EBITDA margin? | Roivant Sciences's last 12 months EBITDA margin is -3589%. |
| What is the current EV/EBITDA multiple of Roivant Sciences? | Current EBITDA multiple of Roivant Sciences is -2.6x. |
| What is the current FCF of Roivant Sciences? | Roivant Sciences's last 12 months FCF is -$335M. |
| What is Roivant Sciences's FCF margin? | Roivant Sciences's last 12 months FCF margin is -1186%. |
| What is the current EV/FCF multiple of Roivant Sciences? | Current FCF multiple of Roivant Sciences is -8.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
